SCM
MBRX icon

Sio Capital Management’s Moleculin Biotech MBRX Stock Holding History

Sio Capital Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-723
Closed -$116K – 48
2023
Q3 		$116K Sell
723
-86
-11% -$17.8K 0.04% 47
2023
Q2 		$176K Sell
809
-1,887
-70% -$498K 0.04% 40
2023
Q1 		$971K Sell
2,696
-69
-2% -$30.2K 0.48% 30
2022
Q4 		$1.1M Hold
2,765
– – 0.41% 32
2022
Q3 		$1.1M Hold
2,765
– – 0.35% 34
2022
Q2 		$1.5M Sell
2,765
-10
-0.4% -$5.82K 0.56% 36
2022
Q1 		$1.85M Hold
2,775
– – 0.61% 37
2021
Q4 		$1.94M Hold
2,775
– – 0.58% 42
2021
Q3 		$3.12M Buy
2,775
+95
+4% +$111K 1% 33
2021
Q2 		$3.69M Buy
2,680
+112
+4% +$153K 0.92% 39
2021
Q1 		$3.93M Buy
+2,568
New +$4.71M 0.8% 43

Other funds holding MBRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWM
Atticus Wealth Management Palm Beach Gardens, Florida $420M AUM 23.31% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Sio Capital Management's MBRX Position: Q4 2023 in Review

Sio Capital Management sold out of Moleculin Biotech (MBRX) in Q4 2023, closing a stake of 723 shares — an estimated $116K sold.

Sio Capital Management first reported a position in MBRX in Q1 2021 and held it in 11 quarters. The position peaked at $3.93M in Q1 2021. 20 funds tracked by Wall St. Rank hold MBRX as of Q4 2023.

  • Sio Capital Management reported no remaining Moleculin Biotech position as of Q4 2023 after selling out during the quarter.
  • Sio Capital Management sold 723 Moleculin Biotech shares in Q4 2023, an estimated $116K.
  • Sio Capital Management first reported a position in Moleculin Biotech in Q1 2021 and held it in 11 quarters.
  • Sio Capital Management's Moleculin Biotech position peaked at $3.93M in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2023.

Based on Sio Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.